Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$7.36 USD
+0.11 (1.52%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $7.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MNMD 7.36 +0.11(1.52%)
Will MNMD be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MNMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNMD
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
MNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
Other News for MNMD
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Mind Medicine announces constructive EOP2 meeting with FDA for MM120
RBC says Mind Medicine 'successful' FDA meeting bodes well for MM120's Phase III